期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 236, 期 4, 页码 2519-2543出版社
WILEY
DOI: 10.1002/jcp.30076
关键词
clinical trial; COVID-19; immunopathogenesis; immunotherapy; SARS-CoV-2
This paper reviews the immunopathogenesis of COVID-19 and the immune response to SARS-CoV-2, highlighting the importance of an effective immune response against the virus. Various methods, including regulation of the immune response and inhibition of viral replication, can be applied to improve the immune response and develop potential immunotherapies.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the coronavirus family that can cause coronavirus disease 2019 (COVID-19). COVID-9 has become a global pandemic with severe health issues around the world. Identifying the accurate immunopathogenesis of the COVID-19 and the immune response against SARS-CoV-2 is necessary for the development of therapeutic approaches and rational drug design. This paper aims to overview the updated clinical data on the immunopathogenesis of the COVID-19 and review the innate and adaptive immune response to SARS-CoV-2. Also, challenges of the immune response to SARS-CoV-2 leading to dysfunctional immune response and their contribution to the progression of the disease have been discussed. To achieve a more efficient immune response, multiple methods could be applied, including regulation of the immune response, augmentation of the immune system against the virus, inhibition of the dysfunctional immune checkpoints, and inhibition of the viral replication/infection. Based on the immune response against SARS-CoV-2 and its dysfunction, we introduce potential immunotherapies as well as reviewing recruiting/completed clinical trials of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据